Cargando…
Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis
Background: Examining the effect of antibiotic resistance, use of intravitreal antibiotics and systemic corticosteroids on visual outcome of eyes with acute endophthalmitis. Methods: We included 226 eyes with acute endophthalmitis, treated using a standardized protocol. Visual outcome up to 12 month...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311540/ https://www.ncbi.nlm.nih.gov/pubmed/35884097 http://dx.doi.org/10.3390/antibiotics11070843 |
_version_ | 1784753617952047104 |
---|---|
author | Wu, Xia-Ni Chen, Yi-Hsing Sharief, Lazha Al-Janabi, Ahmed Al Qassimi, Nura Lightman, Sue Tomkins-Netzer, Oren |
author_facet | Wu, Xia-Ni Chen, Yi-Hsing Sharief, Lazha Al-Janabi, Ahmed Al Qassimi, Nura Lightman, Sue Tomkins-Netzer, Oren |
author_sort | Wu, Xia-Ni |
collection | PubMed |
description | Background: Examining the effect of antibiotic resistance, use of intravitreal antibiotics and systemic corticosteroids on visual outcome of eyes with acute endophthalmitis. Methods: We included 226 eyes with acute endophthalmitis, treated using a standardized protocol. Visual outcome up to 12 months was assessed related to biopsy results, antibiotics resistance and treatment regimens. Results: Vitreous biopsies were more likely to be culture-positive (41.1%) than anterior chamber biopsies (21.6%, p < 0.0001). Antibiotic resistance for amikacin was found in 19 eyes (24.7%), vancomycin in 29 eyes (31.5%) and moxiflocacin in 14 eyes (16.1%). At presentation 91.53% of eyes had BCVA < 20/40, reducing by 1 month to 69.94% (p < 0.0001) and remaining stable at 12 months. There was no difference in visual outcome for those receiving early systemic corticosteroids. Endophthalmitis following cataract surgery (OR 1.66, 1.04–2.66 95% CI, p = 0.03) and receiving intravitreal vancomycin (OR 3.15, 1.18–8.42 95% CI, p = 0.02) were associated with a greater chance of final BCVA ≥ 20/40. Conclusion: Using vitreous taps with intravitreal antibiotics, despite an increase in resistance to both vancomycin and moxifloxacin, results in a final BCVA > 20/200 in half of eyes and ≥20/40 in a third. Early treatment with intravitreal antibiotics should not be delayed. |
format | Online Article Text |
id | pubmed-9311540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93115402022-07-26 Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis Wu, Xia-Ni Chen, Yi-Hsing Sharief, Lazha Al-Janabi, Ahmed Al Qassimi, Nura Lightman, Sue Tomkins-Netzer, Oren Antibiotics (Basel) Article Background: Examining the effect of antibiotic resistance, use of intravitreal antibiotics and systemic corticosteroids on visual outcome of eyes with acute endophthalmitis. Methods: We included 226 eyes with acute endophthalmitis, treated using a standardized protocol. Visual outcome up to 12 months was assessed related to biopsy results, antibiotics resistance and treatment regimens. Results: Vitreous biopsies were more likely to be culture-positive (41.1%) than anterior chamber biopsies (21.6%, p < 0.0001). Antibiotic resistance for amikacin was found in 19 eyes (24.7%), vancomycin in 29 eyes (31.5%) and moxiflocacin in 14 eyes (16.1%). At presentation 91.53% of eyes had BCVA < 20/40, reducing by 1 month to 69.94% (p < 0.0001) and remaining stable at 12 months. There was no difference in visual outcome for those receiving early systemic corticosteroids. Endophthalmitis following cataract surgery (OR 1.66, 1.04–2.66 95% CI, p = 0.03) and receiving intravitreal vancomycin (OR 3.15, 1.18–8.42 95% CI, p = 0.02) were associated with a greater chance of final BCVA ≥ 20/40. Conclusion: Using vitreous taps with intravitreal antibiotics, despite an increase in resistance to both vancomycin and moxifloxacin, results in a final BCVA > 20/200 in half of eyes and ≥20/40 in a third. Early treatment with intravitreal antibiotics should not be delayed. MDPI 2022-06-23 /pmc/articles/PMC9311540/ /pubmed/35884097 http://dx.doi.org/10.3390/antibiotics11070843 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wu, Xia-Ni Chen, Yi-Hsing Sharief, Lazha Al-Janabi, Ahmed Al Qassimi, Nura Lightman, Sue Tomkins-Netzer, Oren Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis |
title | Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis |
title_full | Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis |
title_fullStr | Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis |
title_full_unstemmed | Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis |
title_short | Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis |
title_sort | emerging antibiotic resistance patterns affect visual outcome treating acute endophthalmitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311540/ https://www.ncbi.nlm.nih.gov/pubmed/35884097 http://dx.doi.org/10.3390/antibiotics11070843 |
work_keys_str_mv | AT wuxiani emergingantibioticresistancepatternsaffectvisualoutcometreatingacuteendophthalmitis AT chenyihsing emergingantibioticresistancepatternsaffectvisualoutcometreatingacuteendophthalmitis AT sharieflazha emergingantibioticresistancepatternsaffectvisualoutcometreatingacuteendophthalmitis AT aljanabiahmed emergingantibioticresistancepatternsaffectvisualoutcometreatingacuteendophthalmitis AT alqassiminura emergingantibioticresistancepatternsaffectvisualoutcometreatingacuteendophthalmitis AT lightmansue emergingantibioticresistancepatternsaffectvisualoutcometreatingacuteendophthalmitis AT tomkinsnetzeroren emergingantibioticresistancepatternsaffectvisualoutcometreatingacuteendophthalmitis |